Cardiovascular risk reduction with liraglutide: an exploratory mediation analysis of the LEADER trial

Abstract

The authors identifed HbA1c and urinary albumin:creatinine ratio as potential mediators of the CV effects of liraglutide. These findings warrant further investigation.

Citation
Buse JB, Bain SC, Mann JFE, et al. Diabetes Care 2020;43:1546–52.